Our Services
SERVICES WHEN YOU NEED THEM - AS LONG AS YOU NEED THEM
Titronbio specializes in providing services with our right mix of expertise and education that will help you to quickly come up to speed in your development projects to make the impact an impact. Our experience ranges from reviewing, writing to strategic analysis and tactical implementation. We are poised to support your next move!
Titronbio TM provides consulting services in the area of Cell and Gene therapy including Strategic Drug Development, Data review and analysis- including project based services.
Services include but are not limited to consulting and strategic analysis in the areas of rare diseases, hematological malignancies and solid tumors, regulatory questions including per-IND, IND, BLA - Orphan Drug applications, breakthrough therapy designation - we provide nimble clincial development strategies - fast to market approaches -review, strategy and development for institutional analysis, strategy and content development for professional presentations including scientific meetings, investor conferences and corporate presentations.
"It is of critical importance to get the first impressions right" -
The services of Titronbio TM include review and revision of important corporate presentations and customer outreach on websites and for Due Diligence and listing activities.
Cell and Gene therapy including CAR-T and immuno oncology
analyzing development opportunities on a regional and global scale
developing comprehensive strategies based on corporate goals including tactics
executing with nimble and fast to market approaches including tailored regional approaches depending on regulatory environment
Inquiries
info@titronbio.com
Recent speaking engagements
Disrupting conventional approaches to CAR-T Cell therapies - BCMA target therapies 2022
PR and customer relations
2022-12-07 Montreal, Canada and Shanghai, China - CAR T Global Consultant Inc. Announce their Collaboration with Titronbio - a company founded in Shanghai China by a renowned leader in the field of CAR T and Cell and Gene therapy